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Abstract
Background: In England and Wales breast cancer survival is higher among more affluent women. Our aim was to
investigate the potential of pre-diagnostic factors for explaining deprivation-related differences in survival.
Methods: Individually-linked data from women aged 50–70 in the West Midlands region of England, diagnosed with
breast cancer 1989–2006 and continuously eligible for screening, was retrieved from the cancer registry, screening service
and Clinical Practice Research Datalink. Follow-up was to the end of July 2012. Deprivation was measured at small area
level, based on the quintiles of the income domain of the English indices of deprivation. Consultation rates per woman
per week, time from last breast-related GP consultation to diagnosis, and from diagnosis to first surgery were calculated.
We estimated net survival using the non-parametric Pohar-Perme estimator.
Results: The rate of primary care consultations was similar during the 18 months prior to diagnosis in each deprivation
group for breast and non-breast symptoms. Survival was lower for more deprived women from 4 years after diagnosis.
Lower net survival was associated with more advanced extent of disease and being non-screen-detected. There was a
persistent trend of lower net survival for more deprived women, irrespective of the woman’s obesity, alcohol, smoking or
comorbidity status. There was no significant variation in time from last breast symptom to diagnosis by deprivation.
However, women in more deprived categories experienced significantly longer periods between cancer diagnosis and
first surgery (mean = 21.5 vs. 28.4 days, p = 0.03). Those whose surgery occurred more than 12 weeks following their
cancer diagnosis had substantially lower net survival.
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Conclusions: Our data suggest that although more deprived women with breast cancer display lifestyle factors
associated with poorer outcomes, their consultation frequency, comorbidities and the breast cancer symptoms they
present with are similar. We found weak evidence of extended times to surgical treatment among most deprived
women who were not screen-detected but who presented with symptoms in primary care, which suggests that
treatment delay may play a role. Further investigation of interrelationships between these variables within a larger
dataset is warranted.
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England
Background
In England and Wales there are substantial socio-
economic differentials in breast cancer survival, with sur-
vival being relatively high among more affluent women [1,
2]. There is increasingly strong evidence that these are
due in part to later stage of disease at presentation [3, 4]
and differences in timeliness of diagnosis [5, 6]. Other
potential drivers of late stage at diagnosis include health
system delays in primary and secondary care (practitioner
delays) [7, 8] and differences in patients’ underlying char-
acteristics [9–11] and lifestyle choices [12–16].
Past research has focused on the appraisal by patients of
the seriousness of their symptoms [10], and the possible
sources of delay after presentation using patient experi-
ence surveys and audit data [17–20]. However, to date
there has been little reporting of the connection between
these patterns and the survival of the same women.
Our aim was to investigate the potential of pre-
diagnostic factors for explaining deprivation differences
in survival using the factors shown in the conceptual
framework in Fig. 1. This shows the potential links be-
tween deprivation and the outcome of breast cancer sur-
vival, and patients’ biological, lifestyle, and health
seeking characteristics. The primary outcomes examined
were: the rate of primary care consultation; the time
from last breast-related GP consultation to diagnosis,
and from diagnosis to first surgery; and net survival. We
first describe deprivation-specific variations in women’s
baseline characteristics, pre-diagnostic primary care con-
sultations patterns, symptom presentation, and time in-
tervals from symptom report to diagnosis. We then
examine how net survival varies with deprivation and
with each of these covariates. To do so, we used
individually-linked data from primary care, the screening
service and the cancer registry.
Methods
Data sources and study population
The West Midlands Breast Screening Quality Assurance
Reference Centre provided data on a cohort of women
aged 50–70, diagnosed with primary malignant breast
cancer from 1 April 1989 to 31 March 2006 and eligible
for screening. This dataset included women’s screening
status, their deprivation category and inpatient hospital
stays from Hospital Episode Statistics (HES). Follow-up
was complete up to the end of July 2012 for all women.
A subset of these data was linked to the General Practice
Research Database (GPRD, now subsumed into the Clin-
ical Practice Research Datalink, CPRD), which contains
routinely collected data from primary care including
Fig. 1 Conceptual framework for deprivation-specific differences in breast cancer survival. SD = screen-detected, non-SD = non-screen-detected
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symptoms, diagnoses, tests, therapies and lifestyle-
related information. Only women registered in a practice
which had met a set of basic data quality criteria for the




Deprivation was measured using the income domain of
the English indices of deprivation derived from admin-
istrative data pertaining to the years 2001, 2005 and
2008 [21–23]. These scores are defined for the Lower
Super Output Areas that existed at the 2001 census
(LSOAs, approximately 1500 people). Each woman was
assigned to a deprivation category derived from the
score temporally closest to her date of diagnosis and on
the basis of her address of residence. The scores were
split in five categories based on the quintiles of the na-
tional distribution of the areas. Women were grouped
for some analyses into two categories: less deprived
(quintiles 1 and 2) and middle and more deprived
(quintiles 3, 4 and 5).
Other covariables
Age at diagnosis was grouped into five-year age bands.
Women were categorised as either “screen-detected” or
“not screen-detected”. The latter included women diag-
nosed with interval cancers (when a women’s last screening
attendance had resulted in a negative screen and she had
not yet been invited to a subsequent screening), lapsed and
non-attenders at screening. These are the women whose
cancer was detected symptomatically.
Using information on tumour size, node involvement
and presence of metastases from the cancer registry
database, we defined “extent of disease” for each
woman as: localised (confined to the organ of origin),
regional (spread to adjacent muscle, organ, fat, connect-
ive tissue or regional lymph nodes), and distant (distant
metastases).
Patient characteristics for each woman were derived
from the CPRD data. Smoking (non- or ex-smoker,
current smoker), alcohol consumption status (non-, ex-,
current drinker), and body mass index (BMI; <25 kg/m2,
25 to <30 kg/m2, 30+ kg/m2 [24, 25]) were all extracted
from the patient records. Comorbidities, identified from
the CPRD records using lists of National Health Service
Read Codes (which are the principal method of coding
clinical information in primary care), were combined
into a Charlson score [26]. The Charlson score was also
derived from the HES data. The higher of the two (HES
vs. CPRD) was taken in each case as the patients’ final
comorbidity score.
Primary care consultations
Primary care consultations in the 18 months before diagno-
sis were derived from the CPRD data. These were cate-
gorised as “breast-related” or “not breast-related”. A breast-
related consultation was one which included any mention
of a breast symptom in the Read code list [27]. We also in-
cluded those where the doctor had noted “mammography”,
“female cancer of the breast”, “breast examination” and
other breast-related codes. These were identified by
searches of Read code descriptions (Additional file 1).
These were not all necessarily related to symptom presenta-
tion, but some would have indicated a suspected diagnosis.
However, they all pre-dated histologically-confirmed diag-
nosis and so were counted as a consultation about the
breast that might have then led to diagnosis of breast
cancer. Breast symptoms were grouped into those involving
a lump (including fibroadenoma, nodularity, cyst, axillary
and cervical lymphadenopathy), or not (nipple-related:
bleeding, retraction, discharge, Pagets’ nipple, pain; and
other: skin changes, breast infection, breast pain). Time in
days from a woman’s last breast-related consultation at the
GP to diagnosis, and from diagnosis to first surgery (within
18 months) were calculated for women whose cancer was
not detected through screening and who also reported a
breast symptom in primary care.
Statistical analysis
Consultation rates per woman per week for both breast
and non-breast symptoms were calculated along with
their 95% confidence intervals. Chi-squared tests and
non-parametric tests for trend for continuous variables
[28] were used to examine the association between
deprivation and co-variables. Small numbers precluded
multivariable analyses for these data. All analyses were
carried out in Stata 14 [29].
We estimated net survival for women using the non-
parametric Pohar-Perme estimator [29, 30] by deprivation
and for each covariable. We stratified the net survival
estimates for each deprivation group by each covariable.
Net survival provides an estimate of survival from the can-
cer itself, adjusting for expected mortality from other
causes. We derived individual estimates of expected mor-
tality from ethnic-specific deprivation-adjusted life tables
for England and Wales [31]. We applied locally-weighted
regression to smooth the survival estimates [32, 33] with a
conservative degree of smoothing to maintain the variabil-
ity evident in the more sparse data. Where data were very
sparse, smoothing was not performed.
Results
Sample
Among 28,885 women in the West Midlands dataset,
786 (2.72%) could be linked to CPRD primary care rec-
ord. The matching proportion ranged from 0% in 1989
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to a maximum of 4.96% in 2002, and was 3.25% in the
last year of data available, 2006. The matched sample of
women were similar to the cohort in relation to their
age and distribution of extent of disease at diagnosis.
Fewer women were diagnosed in the period before
1995 (p < 0.001) and a greater proportion were screen-
detected, both reflecting the increasing coverage of the
CPRD over time (Additional file 1: Table S1A). Women
in the sample were more likely to be alive at the end
of follow-up (p < 0.001), and less likely to be deprived
(p < 0.001). Net survival was comparable overall and
by deprivation (Additional file 1: Figure S1A).
Sixty women had no recorded consultations in surgery
with a doctor in the 18 months before diagnosis. Of the
remaining 726 patients, the number of consultations
with a doctor ranged from 1 to 52, with a mean of 14.3.
Half of all women reported no breast symptoms in the
primary care setting during the 18 months before diag-
nosis (50.1%), whilst 40.8% had one breast-related con-
sultation. The remaining 9.0% had more than one
breast-related consultation, with a mean of 2.4 per
woman and a maximum of 6.
Consultation rate
The rate of consultation was similar during the
18 months prior to diagnosis in each deprivation group,
for both breast and non-breast symptoms (Fig. 2). A rise
in the overall rate of consultations was seen from
3 months before diagnosis for breast-related consulta-
tions. The majority of the rise in breast-related consulta-
tions was among women whose cancer was not screen-
detected. Consultation rates did not vary by age, period,
extent of disease, BMI, smoking or alcohol consumption.
Associations between co-variables and deprivation
Women in the more deprived groups were more likely
to have had their cancer identified through screening (p
= 0.013), and were more likely to have regional or distant
spread of disease (p = 0.045). They were also less likely
to be alive at the end of follow up (p = 0.008) (Table 1).
In addition, the primary care data showed that deprived
women were more likely to be current or ex-smokers,
have a higher BMI, but were less likely to be current
drinkers. There was no association between deprivation
and having a comorbidity at diagnosis, nor the number
of distinct breast symptoms reported, nor whether those
who had a breast-related consultation presented with a
lump symptom or not (Table 2).
Net survival by deprivation
Survival was lower for more deprived women from
4 years after diagnosis (Fig. 3). There was a suggestion
that more deprived groups experienced worse survival,
though the apparent trend was compatible with chance
variation.
Net survival by covariables
Lower net survival was associated with more advanced
extent of disease and not being screen-detected. There
was some evidence that reporting a non-lump symptom
led to poorer survival (among those not screen-detected
who reported a symptom).
The presence of comorbidity was strongly associated
with poorer net survival, especially over longer time pe-
riods (Fig. 4a), and there was also some evidence that
obesity was also associated with poorer outcomes
(Fig. 4b). There was little evidence of difference in net
survival from breast cancer by smoking status, or by al-
cohol consumption status (Fig. 4c and d).
We examined the potential interaction between
deprivation and each of these co-variables by deriving
net survival for each of their sub-groups. Throughout,
there was a persistent trend of lower net survival for
more deprived women. This disadvantage was present ir-
respective of the woman’s obesity, alcohol, smoking or
Fig. 2 Consultation rates in the 12 weeks prior to diagnosis by
deprivation: women diagnosed in West Midlands with invasive
breast cancer 1989–2006 found within the CPRD dataset (N = 786);
a breast-related symptoms, b non-breast-related symptoms
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Table 1 Distribution of co-variables by deprivation quintile among all women (N = 786)
Total Least deprived 2 3 4 Most deprived p-valuea
n (%) n (%) n (%) n (%) n (%) n (%)
Total 786 (100) 211 (100) 213 (100) 140 (100) 112 (100) 110 (100)
Vital status at end of follow up
Alive 567 (72.1) 165 (78.2) 154 (72.3) 106 (75.7) 76 (67.9) 66 (60.0) 0.008
Dead 219 (27.9) 46 (21.8) 59 (27.7) 34 (24.3) 36 (32.1) 44 (40.0)
Age groups
50–54 191 (24.3) 49 (23.2) 57 (26.8) 29 (20.7) 27 (24.1) 29 (26.4) 0.707
55–59 174 (22.1) 48 (22.7) 48 (22.5) 35 (25.0) 21 (18.8) 22 (20.0)
60–64 216 (27.5) 66 (31.3) 58 (27.2) 33 (23.6) 33 (29.5) 26 (23.6)
65–70 205 (26.1) 48 (22.7) 50 (23.5) 43 (30.7) 31 (27.7) 33 (30.0)
Extent of disease at diagnosis
Localised 437 (55.6) 127 (60.2) 118 (55.4) 81 (57.9) 59 (52.7) 52 (47.3) 0.045
Regional 255 (32.4) 64 (30.3) 65 (30.5) 45 (32.1) 39 (34.8) 42 (38.2)
Distant 24 (3.1) 3 (1.4) 5 (2.3) 3 (2.1) 4 (3.6) 9 (8.2)
Missing 70 (8.9) 17 (8.1) 25 (11.7) 11 (7.9) 10 (8.9) 7 (6.4)
Screening groups
Screen-detected cancer 316 (40.2) 112 (53.1) 119 (55.9) 64 (45.7) 65 (58.0) 74 (67.3) 0.013
Not screen-detected cancer 434 (55.2) 91 (43.1) 83 (39.0) 67 (47.9) 45 (40.2) 30 (27.3)
Missing 36 (4.6) 8 (3.8) 11 (5.2) 9 (6.4) 2 (1.8) 6 (5.5)
Period of diagnosis
1989–1994 81 (10.3) 18 (8.5) 22 (10.3) 13 (9.3) 11 (9.8) 17 (15.5) 0.011
1995–2000 283 (36.0) 79 (37.4) 64 (30.0) 57 (40.7) 32 (28.6) 51 (46.4)
2001–2006 422 (53.7) 114 (54.0) 127 (59.6) 70 (50.0) 69 (61.6) 42 (38.2)
Smoking status
Non- or ex-smoker 541 (68.8) 159 (75.4) 154 (72.3) 94 (67.1) 74 (66.1) 60 (54.5) 0.002
Current smoker 222 (28.2) 45 (21.3) 55 (25.8) 42 (30.0) 33 (29.5) 47 (42.7)
Missing 23 (2.9) 7 (3.3) 4 (1.9) 4 (2.9) 5 (4.5) 3 (2.7)
Alcohol consumption status
Non-drinker 84 (10.7) 17 (8.1) 13 (6.1) 19 (13.6) 12 (10.7) 23 (20.9) <0.001
Current drinker 569 (72.4) 161 (76.3) 171 (80.3) 96 (68.6) 72 (64.3) 69 (62.7)
Ex-drinker 81 (10.3) 19 (9.0) 16 (7.5) 14 (10.0) 18 (16.1) 14 (12.7)
Missing 52 (6.6) 14 (6.6) 13 (6.1) 11 (7.9) 10 (8.9) 4 (3.6)
BMI (kg/m2)
< 25 kg/m2 305 (38.8) 84 (39.8) 99 (46.5) 53 (37.9) 40 (35.7) 29 (26.4) 0.001
25 to <30 235 (29.9) 73 (34.6) 50 (23.5) 43 (30.7) 32 (28.6) 37 (33.6)
30+ 189 (24) 41 (19.4) 49 (23.0) 29 (20.7) 32 (28.6) 38 (34.5)
Missing 57 (7.3) 13 (6.2) 15 (7.0) 15 (10.7) 8 (7.1) 6 (5.5)
Charlson score
0 684 (87) 191 (90.5) 185 (86.9) 124 (88.6) 93 (83.0) 91 (82.7) 0.202
1+ 102 (13) 20 (9.5) 28 (13.1) 16 (11.4) 19 (17.0) 19 (17.3)
a P-values are derived from X2 tests for categorical variables and non-parametric tests for trend for continuous variables (BMI, breast-related consultations). All tests
exclude missing values
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comorbidity status (Additional file 1: Figure S2B). Fur-
thermore, the magnitude of the survival difference was
similar for all co-variables.
Time from last breast-related consultation to diagnosis
and from diagnosis to surgery
We examined variations in the time elapsed from last
symptom report (last breast-related consultation) to can-
cer diagnosis among women whose cancer was not
screen-detected and who reported breast symptoms in
primary care (N = 331). We also analysed the time
elapsed from diagnosis to first surgery within 18 months
of diagnosis for women whose diagnosis date was re-
corded earlier than the date of their surgery (N = 212).
There was no significant variation in time from last
breast symptom to diagnosis by deprivation or any other
co-variable (Table 3), although women in the most de-
prived group appeared to have longer waiting times than
the other four quintiles, as did obese women, and
women who did not present with a breast lump.
By contrast, there was evidence that women in more
deprived categories experienced longer periods between
cancer diagnosis and first surgery: 21.5 days in quintiles
1, 2 and 3 compared to 28.4 days for quintiles 4 and 5
(p-value 0.03). Among women in the study, those diag-
nosed with distant disease had longer mean time to sur-
gery compared with those with either regional or
localised disease, but this difference may have reflected
chance variation (p = 0.14).
Among these same non-screen-detected women there
was little evidence of survival differences by time from
last breast-related consultation to diagnosis within the
first 5 years. After this, women for whom the time inter-
val from consultation to diagnosis was 43–84 days (6–
12 weeks) had higher survival, although not significantly
so (Fig. 5a). Conversely, those whose surgery occurred
Table 2 Distribution of co-variables by deprivation quintile among women who were not screen-detected (N = 434)
Total Least deprived 2 3 4 Most deprived p-valuea
n (%) n (%) n (%) n (%) n (%) n (%)
Total 434 (100) 112(100) 119 (100) 64 (100) 65 (100) 74 (100)
Number of distinct breast symptoms reported in 18mths before diagnosis
0 103 (23.7) 37 (33.0) 22 (18.5) 12 (18.8) 16 (24.6) 16 (21.6) 0.137
1 278 (64.1) 66 (58.9) 77 (64.7) 45 (70.3) 39 (60.0) 51 (68.9)
2+ 53 (12.2) 9 (8.0) 20 (16.8) 7 (10.9) 10 (15.4) 7 (9.5)
Lump symptom
No 137 (31.6) 43 (38.4) 38 (31.9) 11 (17.2) 22 (33.9) 23 (31.1) 0.069
Yes 297 (68.4) 69 (61.6) 81 (68.1) 53 (82.8) 43 (66.2) 51 (68.9)
a P-values are derived from X2 tests for categorical variables and non-parametric tests for trend for continuous variables (BMI, breast-related consultations). All tests
exclude missing values
Fig. 3 Net survival by deprivation: all women (N = 786).
Footnotes: 95% CIs overlap, so are not displayed for clarity. Survival from date of cancer diagnosis to death, or the end of follow-up
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more than 12 weeks following their cancer diagnosis had
substantially lower net survival compared to those
whose surgery took place within 12 weeks (Fig. 5b). This
difference was evident from cancer diagnosis onwards.
Discussion
Our data suggest that although more deprived women
display lifestyle factors associated with poorer outcomes,
their consultation frequency for both breast and non-
breast symptoms, their comorbidities and the type of
breast cancer symptoms they present with are similar.
This interpretation is supported by the lack of difference
in consultation patterns by extent of disease, BMI, smok-
ing or alcohol consumption status coupled with the per-
sistence of deprivation differences in survival within the
sub-groups of these co-variables. We found some evi-
dence of extended times to surgical treatment among
most deprived women who were not screen-detected
but who presented with symptoms in primary care. This
potentially suggests that treatment delay may play a role,
either due to a greater proportion of deprived women
receiving neo-adjuvant treatment, or due to differences
in the way more deprived patients interact with the
healthcare system. Further investigation of the interrela-
tionships between these variables within a larger and
more detailed dataset is warranted.
These data were from a centre of excellence in breast
cancer registration, and although small numbers limited
our ability to perform multivariable analyses, our sample
was representative, in terms of survival and most other
characteristics, of the cohort from which they were drawn.
The sample was somewhat less deprived than the cohort
of women from which they came which is likely to be due
to the profiles of the GP practices that contributed to the
CPRD dataset within the West Midlands. In most cases
there was less than 10% missing data in the analysis. The
data available included women diagnosed some time ago,
however, despite the changes in the healthcare system in
the years since these data were collected, this study high-
lights some important areas that are less likely to have
changed greatly. Despite a persistent deprivation gap in
survival, we have found no difference in rate of consult-
ation between the more and less deprived. In addition,
changes in the system have resulted in almost unchanged
high proportions of diagnoses after emergency admission
for certain cancers (such as colon and lung).
Women who were not screen-detected and who pre-
sented with symptoms in primary care are those for
whom policies encouraging early diagnosis are likely to
be most effective. However, time from last breast-related
consultation to diagnosis in this group was not signifi-
cantly related to any of the variables investigated. This
may suggest that patient delay prior to diagnosis is not
such an important driver of survival differences within
this cohort as might be assumed. On the other hand,
time from last consultation to surgery in this group was
Fig. 4 Net survival for all women in the sample (N= 786) by (a) the presence of comorbidities, (b) BMI, (c) smoking status and (d) alcohol consumption.
Footnotes: Estimates smoothed. Survival from date of cancer diagnosis to death, or the end of follow-up
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longer among more deprived women, overweight or
obese women, those who had a comorbidity, and those
who were older. This potentially suggests that
symptomatically-detected women are being referred and
diagnosed just as quickly, regardless of their socio-
demographic characteristics, but that differences in time
to surgical treatment emerge after diagnosis. Such differ-
ences might be in part due to greater complexity in pre-
paring more comorbid women, or women with more
advanced stage of disease, for surgery, or due to
Table 3 Mean time from last breast symptom reported to diagnosis (N = 331) and to surgery (N = 212) by co-variables, among
non-screen-detected women who also reported breast symptoms
Time from last breast-related consultation to diagnosis Time from diagnosis to surgery
N (%) Mean (range), days P value (trend) N (%) Mean (range), days P value (trend)a
Total 331 (100.0) 16.0 (1–509) 212 (100.0) 23.7 (1–199)
Deprivation
Least deprived 75 (22.7) 15.6 (1–444) 0.299 48 (22.6) 22.1 (7–117) 0.034
2 97 (29.3) 15.1 (1–509) 59 (27.8) 21.5 (3–156)
3 52 (15.7) 15.8 (2–116) 34 (16.0) 20.9 (1–162)
4 49 (14.8) 15.0 (2–373) 35 (16.5) 27.6 (13–136)
Most deprived 58 (17.5) 19.3 (1–389) 36 (17.0) 29.2 (10–199)
Extent
1 162 (48.9) 14.6 (1–444) 0.554 110 (51.9) 22.0 (3–139) 0.137
2 134 (40.5) 17.2 (1–509) 89 (42.0) 24.3 (1–199)
3 12 (3.6) 13.9 (2–222) 4 (1.9) 48.5 (22–156)
missing 23 (6.9) 9 (4.2)
Age
50–54 89 (26.9) 19.4 (1–509) 0.144 59 (27.8) 21.8 (2–162) 0.790
55–59 62 (18.7) 14.6 (1–258) 45 (21.2) 25.2 (3–153)
60–64 89 (26.9) 15.9 (2–109) 54 (25.5) 23.9 (1–151)
65–70 91 (27.5) 14.1 (1–389) 54 (25.5) 24.3 (6–199)
BMI
< 25 normal 141 (42.6) 15.0 (1–444) 0.235 85 (40.1) 21.3 (2–199) 0.590
25to < 30 overweight 97 (29.3) 14.5 (1–509) 68 (32.1) 26.7 (7–156)
30+ obese 68 (20.5) 20.1 (4–444) 49 (23.1) 22.4 (1–162)
missing 25 (7.6) 10 (4.7)
Smoking
non- or ex-smoker 219 (66.2) 15.4 (1–509) 0.371 142 (67.0) 23.4 (1–156) 0.881
current smoker 102 (30.8) 17.5 (1–258) 64 (30.2) 24.3 (3–199)
missing 10 (3.0) 6 (2.8)
Alcohol consumption status
non-drinker 37 (11.2) 14.0 (2–101) 0.989 26 (12.3) 21.6 (11–53) 0.857
current drinker 242 (73.1) 16.4 (1–509) 155 (73.1) 24.1 (1–199)
ex-drinker 33 (10.0) 15.4 (2–393) 23 (10.8) 21.3 (6–106)
missing 19 (5.7) 8 (3.8)
Charlson score
0 298 (90.0) 15.8 (1–509) 0.414 188 (88.7) 23.1 (1–199) 0.103
1+ 33 (10.0) 17.4 (2–109) 24 (11.3) 28.9 (12–106)
Lump symptom
No 59 (17.8) 20.0 (1–444) 0.206 35 (16.5) 23.1 (3–199) 0.827
Yes 272 (82.2) 15.2 (1–509) 177 (83.5) 23.8 (1–162)
a Non-parametric tests for trend statistics and means exclude missing values and were performed on log-transformed values
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differences in the way more deprived women navigate the
healthcare system. In order to be able to draw firm con-
clusions about this, we would need specific information
on treatments received including the rationale behind de-
cisions made, in particular in relation to timing, adjuvant
therapies administered, patient input into these decisions,
and patient adherence. Reliable recurrence information
for each woman over a medium to long period of follow-
up would also be required.
There are some well-established relationships between
deprivation and smoking, BMI, alcohol consumption,
screening and stage at diagnosis [12–16, 34–36] but few
have been investigated using the primary care data to date.
BMI was associated in this sample with both deprivation
and time to surgery, and may therefore explain some of the
relationship between deprivation and survival. Conversely,
the presence of comorbidities, while closely associated with
survival and time to surgery, was not significantly related to
deprivation. This contrasts with previous work where co-
morbidity was more frequent among the more deprived
[37, 38]. However, in our data very few women had more
than one comorbidity, probably because we included only
women aged 50–70 (those eligible for breast screening).
These women are generally healthier than the older women
with breast cancer.
Conclusions
We have previously shown that differences in survival by
deprivation are evident among both women whose can-
cer was screen-detected and those not screen-detected
[36] and that these differences are not entirely explained
by adjustment for stage of disease and treatment re-
ceived [39]. In those analyses we made corrections for
potential biases due to lead time [40] and over-diagnosis.
This preliminary exploration of a linked sub-sample of
these same data has highlighted both similarities and dif-
ferences in the characteristics of women by deprivation
status. It has shown a reassuring lack of difference in the
impact of deprivation on consultation patterns, and a
lack of association between lifestyle factors associated
with deprivation and survival. On the other hand, our
data point to some potential differences in time to surgi-
cal treatment that should be explored further. Our ana-
lysis demonstrates the feasibility of using primary care
data to add to our understanding of what underlies sur-
vival differences. Larger samples linked to richer data on
treatment decisions and pathways are required to eluci-
date these patterns further.
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